Immunic

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Immunic (IMUX – Research Report) with bullish sentiments. Trevena (TRVN) JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena today and set a price target of $4.00. The company’s […]